These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 35800411)

  • 21. Cardiovascular effects of antidiabetic drugs.
    Sørensen AM; Christensen MB
    Drugs Today (Barc); 2018 Sep; 54(9):547-559. PubMed ID: 30303495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of GLP-1 receptor agonists and SGLT-2 inhibitors in heart transplant patients with type 2 diabetes: Initial report from a cardiometabolic center of excellence.
    Sammour Y; Nassif M; Magwire M; Thomas M; Fendler T; Khumri T; Sperry BW; O'Keefe J; Kosiborod M
    J Heart Lung Transplant; 2021 Jun; 40(6):426-429. PubMed ID: 33745782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparing the Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists with Sodium-Glucose Cotransporter 2 Inhibitors for Obese Type 2 Diabetes Patients Uncontrolled on Metformin: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
    Ding L; Sun B; Xiao X
    Int J Endocrinol; 2020; 2020():1626484. PubMed ID: 33061964
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel Antidiabetic Agents: Cardiovascular and Safety Outcomes.
    Siasos G; Bletsa E; Stampouloglou PK; Paschou SA; Oikonomou E; Tsigkou V; Antonopoulos AS; Vavuranakis M; Tousoulis D
    Curr Pharm Des; 2020; 26(46):5911-5932. PubMed ID: 33167826
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis.
    Zheng SL; Roddick AJ; Aghar-Jaffar R; Shun-Shin MJ; Francis D; Oliver N; Meeran K
    JAMA; 2018 Apr; 319(15):1580-1591. PubMed ID: 29677303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis.
    de Wit HM; Te Groen M; Rovers MM; Tack CJ
    Br J Clin Pharmacol; 2016 Jul; 82(1):301-14. PubMed ID: 26935973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis.
    Fei Y; Tsoi MF; Cheung BMY
    Cardiovasc Diabetol; 2019 Aug; 18(1):112. PubMed ID: 31462224
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pleiotropic effects of antidiabetic agents on renal and cardiovascular outcomes: a meta-analysis of randomized controlled trials.
    Chewcharat A; Takkavatakarn K; Isaranuwatchai S; Katavetin P; Praditpornsilpa K; Eiam-Ong S; Susantitaphong P
    Int Urol Nephrol; 2020 Sep; 52(9):1733-1745. PubMed ID: 32524495
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical pharmacology of antidiabetic drugs: What can be expected of their use?
    Scheen AJ
    Presse Med; 2023 Mar; 52(1):104158. PubMed ID: 36565754
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Renal effects of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and renal impairment.
    Weir MR
    Postgrad Med; 2019 Aug; 131(6):367-375. PubMed ID: 31132013
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
    Scheen AJ
    Circ Res; 2018 May; 122(10):1439-1459. PubMed ID: 29748368
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline.
    Li S; Vandvik PO; Lytvyn L; Guyatt GH; Palmer SC; Rodriguez-Gutierrez R; Foroutan F; Agoritsas T; Siemieniuk RAC; Walsh M; Frere L; Tunnicliffe DJ; Nagler EV; Manja V; Åsvold BO; Jha V; Vermandere M; Gariani K; Zhao Q; Ren Y; Cartwright EJ; Gee P; Wickes A; Ferns L; Wright R; Li L; Hao Q; Mustafa RA
    BMJ; 2021 May; 373():n1091. PubMed ID: 33975892
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis.
    Kramer CK; Ye C; Campbell S; Retnakaran R
    JACC Heart Fail; 2018 Oct; 6(10):823-830. PubMed ID: 30196071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT-2 inhibitors and GLP-1 receptor agonists.
    Bonaventura A; Carbone S; Dixon DL; Abbate A; Montecucco F
    J Intern Med; 2019 Jul; 286(1):16-31. PubMed ID: 30888088
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
    Palmer SC; Tendal B; Mustafa RA; Vandvik PO; Li S; Hao Q; Tunnicliffe D; Ruospo M; Natale P; Saglimbene V; Nicolucci A; Johnson DW; Tonelli M; Rossi MC; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque LI; Lloyd A; Ahmad N; Liu Y; Tiv S; Millard T; Gagliardi L; Kolanu N; Barmanray RD; McMorrow R; Raygoza Cortez AK; White H; Chen X; Zhou X; Liu J; Rodríguez AF; González-Colmenero AD; Wang Y; Li L; Sutanto S; Solis RC; Díaz González-Colmenero F; Rodriguez-Gutierrez R; Walsh M; Guyatt G; Strippoli GFM
    BMJ; 2021 Jan; 372():m4573. PubMed ID: 33441402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes.
    Singh AK; Singh R
    World J Cardiol; 2022 Jun; 14(6):329-342. PubMed ID: 35979179
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factors Influencing the Prescribing Preferences of Physicians for Drug-Naive Patients with Type 2 Diabetes Mellitus in the Real-World Setting in Japan: Insight from a Web Survey.
    Murayama H; Imai K; Odawara M
    Diabetes Ther; 2018 Jun; 9(3):1185-1199. PubMed ID: 29696567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study.
    Kim YG; Han SJ; Kim DJ; Lee KW; Kim HJ
    Cardiovasc Diabetol; 2018 Jun; 17(1):91. PubMed ID: 29935543
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
    Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
    Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glycaemic Control in Diabetes.
    Müller-Wieland D; Brandts J; Verket M; Marx N; Schütt K
    Handb Exp Pharmacol; 2022; 270():47-71. PubMed ID: 34467427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.